[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599563":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":43,"centralContacts":47,"locations":55,"responsibleParty":69,"collaborators":51,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":51,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":51,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":57,"whyStopped":51,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Alexandria University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"group p","PLACEBO_COMPARATOR","patients will receive 0.9% normal saline",[13],"Other: 0.9% normal saline",{"label":15,"type":16,"description":17,"interventionNames":18},"group M","ACTIVE_COMPARATOR","patients will receive 10 mg metoclopramide",[19],"Drug: Metoclopramide 10mg",{"label":21,"type":16,"description":22,"interventionNames":23},"group D","patients will receive 8 mg dexamethasone",[24],"Drug: Dexamethasone",[26,32,38],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"0.9% normal saline","patients in group P will receive 0.9% normal saline",[9],[31],"group P",{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","Metoclopramide 10mg","patients in group M will receive 10 mg metoclopramide",[15],[15],{"type":33,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Dexamethasone","patients in group D will receive 8 mg dexamethasone",[21],[21],[44],{"name":45,"affiliation":5,"role":46},"sarah m elgamal, MD","PRINCIPAL_INVESTIGATOR",[48,53],{"name":45,"role":49,"phone":50,"phoneExt":51,"email":52},"CONTACT","01005496440",null,"sarahelgamal1990@yahoo.com",{"name":54,"role":49,"phone":51,"phoneExt":51,"email":51},"moutaz ghandour, MD",[56],{"facility":5,"status":57,"city":58,"state":51,"zip":51,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"RECRUITING","Alexandria","Egypt","EG",{"type":62,"coordinates":63},"Point",[64,65],29.91582,31.20176,{"lat":65,"lon":64},[68],{"name":45,"role":49,"phone":50,"phoneExt":51,"email":52},{"type":46,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":51,"oldOrganization":51},"sarah mohamed","lecturer","100599563","dexamethasone-versus-metoclopramide-for-prophylaxis-of-nausea-and-vomiting-after-cataract-surgery-100599563",false,"NCT07086118","Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery","Efficacy of Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery: A Double-blind Randomized Controlled Study","Inclusion Criteria:\n\n* Age: 40-80 years, both sexes.\n* ASA physical status class I to III.\n\nExclusion Criteria:\n\n* history of motion sickness\n* patients with gastrointestinal disorders or gastro-oesophageal reflux\n* patients taking medications with known antiemetic activity\n* previous postoperative vomiting\n* allergy to bupivacaine\n* allergy to metoclopramide or dexamethasone","ALL","40 Years","80 Years",{"count":83,"type":84},210,"ESTIMATED","INTERVENTIONAL",[87],"NA","Postoperative nausea and vomiting (PONV) is a common consequence of ambulatory surgery, affecting up to 80% of high-risk patients and 20-30% overall. Despite being widespread, a prior survey found that patients are more averse to PONV than pain and other significant postoperative problems. Furthermore, even mild cases of PONV can have serious repercussions, such as postanesthesia care unit (PACU) workflow disruption, delayed discharges, higher medical costs, and lower patient satisfaction.PONV following intraocular surgery can be unpleasant and may lead to serious complications including suprachoroidal hemorrhage (SCH). SCH is a potentially serious condition that occurs when the posterior ciliary arteries or vortex veins burst, resulting in blood in the suprachoroidal region.\n\nThe hypothesis is that dexamethasone will lower the incidence of PONV after cataract surgery when compared with metoclopramide.",[90,39],"Cataract",[92,93],"dexamethasone","cataract surgery","2025-07-18",{"date":96,"type":97},"2025-07-25","ACTUAL",{"date":99,"type":97},"2025-05-01",{"date":101,"type":84},"2025-12-01",{"name":5,"class":6},1]